Natural Products
Gallic acid
| Catalog No. | CFN99624 |  |
| CAS No. | 149-91-7 | |
| Molecular Weight: | 170.1 | |
| Molecular Formula | C7H6O5 | |
| DBs | [PubChem]:274950529 [ChEMBL]:30778 [PCIDB]:2647 |
Standard InChI:
InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)
Biological Activity
Gallic acid and curcumin are natural phenolic compounds, both have cytotoxic activity in relation to their radical modulating activity, induce apoptosis by different mechanisms, and gallic acid produces higher amounts of radicals and more efficiently scavenged the superoxide anion radical.[1]
Gallic acid has antioxidant activities at a higher concentration is mainly due to the scavenging of hydrogen peroxide in this system, and the pro-oxidant mechanism is most likely due to the strong reducing power and weak metalchelating ability.[2]
Gallic acid (GA) has a strong anti-tyrosinase activity (IC50=3.59x10(-6) M), effectively suppresses murine tyrosinase action and the amount of melanin, down-regulates the RS generation and enhanced the glutathione (GSH)/oxidized glutathione (GSSG) ratio, indicates that GA exerts antimelanogenic activity coupled with antioxidant properties by suppressing RS generation and maintaining a higher glutathione (GSH)/oxidized glutathione (GSSG) ratio.[3]
Gallic acid, a histone acetyltransferase inhibitor, can efficiently block neuronal cell death by downregulating the expression of cytokines and the in vivo levels of NF-κB acetylation, suggest that GA is a possible therapeutic approach for alleviating the inflammatory progression of Alzheimer disease.[4]
Gallic acid is a potent inhibitor of brush border sucrase and other disaccharidases and thus could potentially interfere with the digestive functions of the intestine.[5]
Gallic acid has anti-tumor activity, combination of gallic acid and cisplatin increased the tumor cell apoptosis compared with the treatment with cisplatin alone, suggests that the combination of gallic acid with an anti-cancer drug, including cisplatin, may be an effective protocol for lung cancer therapy.[6]
Product
References
[1] Nogaki A, Satoh K, Iwasaka K, et al. Anticancer Res, 1998, 18(5A):3487-91.
[2] Yen G C, Duh P D, Tsai H L. Food Chem, 2002, 79(3):307-13.
[3] Kim Y J. Biol Pharm Bull, 2007, 30(6):1052-5.
[4] Kim M J, Seong A R, Yoo J Y, et al. Mol Nut Food Res, 2011, 55(12):1798–808.
[5] Gupta N, Gupta S, Mahmood A. Nut Res, 2007, 27(4):230-5.
[6] Kawada M, Ohno Y, Ri Y, et al. Anti-cancer Drugs, 2001, 12(10):847-52.
[7] Sawant L, Prabhakar B, Pandita N. J Anal Bioanal Techniques, 2010, 1(1):1-4.
Product Use Citation
